Kancera AB (publ) (STO:KAN)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.458
+0.088 (6.42%)
Aug 1, 2025, 5:00 PM CET
6.42%
Market Cap176.69M
Revenue (ttm)n/a
Net Income (ttm)-44.53M
Shares Out121.19M
EPS (ttm)-0.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume107,756
Average Volume189,823
Open1.374
Previous Close1.370
Day's Range1.320 - 1.480
52-Week Range0.800 - 2.980
Beta1.13
RSI46.92
Earnings DateAug 22, 2025

About Kancera AB

Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (pub... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol KAN
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.